US drug regulator on Tuesday (August 9) ratified the Jynneos Nordic Bavaria vaccine for emergency use through intradermal injection in individuals aged 18 years and over who are determined to be at high risk of monkeypox infections. Authorization of the Food and Drug Administration (FDA (FDA) will increase the total amount of doses available for up to five times.
According to estimates distributed during briefing by the Monkeypox White House response coordinator, Bob Fenton, that means up to two million doses available from 400,000 left on Tuesday.This also allows individuals younger than 18 years to receive vaccines with subcutaneous injection ...
